Global Health
Listing performance
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Issue details
- IPO date
- 03 Nov 2022 – 07 Nov 2022
- Listing date
- 16 Nov 2022
- Face value
- ₹2 per share
- Issue price
- ₹336 per share
- Lot size
- 44 shares
- Total issue size
- ₹2,206 Cr
- Market cap at offer price
- ₹9,011 Cr
- Promoter holding
- 35.00% → 33.00% pre-issue → post-issue
- ISIN
- INE474Q01031
- Registrar
- Kfin Technologies Ltd.
- Lead managers
- Kotak Mahindra Capital Co.Ltd.
- Registered office
- Medanta Mediclinic, E-18, Defence Colony, New Delhi
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 1,96,92,584 | — | — |
| Market maker | 0 | — | — |
Application size
Minimum 44 shares per lot, in multiples, at ₹336
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 44 | ₹14,784 |
| Retail (max) | 13 | 572 | ₹1,92,192 |
| S-HNI (min) | 14 | 616 | ₹2,06,976 |
| S-HNI (max) | 67 | 2,948 | ₹9,90,528 |
| B-HNI (min) | 68 | 2,992 | ₹10,05,312 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Valuation and performance
Valuation at offer price
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 7.78 | — |
| P/E (×) | 43.19 | — |
| Market cap | — | ₹9,011 Cr |
Key performance indicators
- Return on net worth
- 12.14%
- ROCE
- 16.30%
- Debt / equity
- 0.50
- PAT margin
- 9.00%
- EBITDA margin
- 21.92%
- NAV per share
- ₹63.82
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Global Health
Global Health Limited was incorporated as Global Health Private Limited on August 13, 2004 at New Delhi and converted into a public limited company, renamed Global Health Limited, pursuant to a fresh certificate of incorporation dated August 11, 2021. Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon, the company operates under the 'Medanta' brand and, per the CRISIL Report, was one of the largest private multi-speciality tertiary care providers in North and East India by bed capacity and operating revenues for fiscal 2022. Its network comprises five operating hospitals — Medanta – The Medicity, Gurugram (flagship), Medanta Super Speciality Hospital, Indore, Medanta Abdur Razzaque Ansari Memorial Weavers' Hospital, Ranchi, Medanta Lucknow Hospital (via subsidiary MHPL) and Jay Prabha Medanta Super Specialty Hospital, Patna (via subsidiary GHPPL) — six multi-speciality clinics (DLF Cybercity Gurugram, Delhi Airport, south Delhi, Darbhanga, Patna and Subhash Chowk Gurugram) and a Noida hospital under construction expected to commence operations in Fiscal 2025. It generates almost all revenue from these facilities, led by inpatient admissions (82.87% of fiscal 2022 income from healthcare services) alongside outpatient care, diagnostics and pharmacy; consolidated revenue from operations was ₹21,665.89 million with profit after tax of ₹1,962.02 million in fiscal 2022. The sole promoter, Dr. Naresh Trehan, held 35.00% of the pre-offer equity capital.
Company Analysis
from RHPGlobal Health Limited, operating under the 'Medanta' brand founded by Dr. Naresh Trehan, is one of the largest private multi-speciality tertiary care providers in the North and East regions of India, running a network of five hospitals and six multi-speciality clinics.
Global Health Limited was incorporated as Global Health Private Limited on August 13, 2004 at New Delhi and converted into a public limited company, renamed Global Health Limited, pursuant to a fresh certificate of incorporation dated August 11, 2021. Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon, the company operates under the 'Medanta' brand and, per the CRISIL Report, was one of the largest private multi-speciality tertiary care providers in North and East India by bed capacity and operating revenues for fiscal 2022. Its network comprises five operating hospitals — Medanta – The Medicity, Gurugram (flagship), Medanta Super Speciality Hospital, Indore, Medanta Abdur Razzaque Ansari Memorial Weavers' Hospital, Ranchi, Medanta Lucknow Hospital (via subsidiary MHPL) and Jay Prabha Medanta Super Specialty Hospital, Patna (via subsidiary GHPPL) — six multi-speciality clinics (DLF Cybercity Gurugram, Delhi Airport, south Delhi, Darbhanga, Patna and Subhash Chowk Gurugram) and a Noida hospital under construction expected to commence operations in Fiscal 2025. It generates almost all revenue from these facilities, led by inpatient admissions (82.87% of fiscal 2022 income from healthcare services) alongside outpatient care, diagnostics and pharmacy; consolidated revenue from operations was ₹21,665.89 million with profit after tax of ₹1,962.02 million in fiscal 2022. The sole promoter, Dr. Naresh Trehan, held 35.00% of the pre-offer equity capital.
Objects of the Issue
- Investment in two of our Subsidiaries, GHPPL and MHPL, in the form of debt or equity for repayment/prepayment of borrowings of such Subsidiaries ₹3,750.00 million p.20
- General corporate purposes ₹1,017.01 million p.20
Issue Structure
- Total Issue
- 65,641,952* Equity Shares aggregating to ₹22,055.70 million*
- Fresh Issue
- 14,880,952* Equity Shares aggregating up to ₹5,000 million
- Offer for Sale
- 50,761,000 Equity Shares aggregating to ₹17,055.70 million*, comprising 50,661,000 Equity Shares aggregating to ₹17,022.10 million* by Anant Investments (Investor Selling Shareholder) and 100,000 Equity Shares aggregating to ₹33.60 million* by Sunil Sachdeva (jointly held with Suman Sachdeva)
- Price Band
- Minimum (Floor) price ₹319 per Equity Share to maximum (Cap) price ₹336 per Equity Share; Offer Price finalized at ₹336 per Equity Share
- Lot Size
- 44 Equity Shares and in multiples of 44 Equity Shares thereafter
- Face Value
- ₹2 each
Business Model
The company earns revenue by providing healthcare services at its hospitals and clinics: primarily inpatient (IPD) admissions and advanced medical treatments — ₹17,405.99 million, or 82.87% of fiscal 2022 income from healthcare services — supplemented by outpatient (OPD) consultations, diagnostic laboratory services, executive health screening and in-house pharmacy sales. Patients pay out-of-pocket (59.97% of fiscal 2022 in-patient revenue in cash) or via third-party administrators/insurers (25.14%), government schemes such as CGHS/ECHS/Indian Railways (9.15%) and corporates/public sector undertakings (5.74%).
Business Segments
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Dr. Naresh Trehan | Promoter | 35.00% | 33.06% |
Leadership
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.